Clinical outcomes and risk factors for local failure and visual impairment in patients treated with Ru-106 brachytherapy for uveal melanoma
Ruthenium-106 brachytherapy yields good local control and visual outcomes in patients with choroidal melanoma. Juxtapapillary tumours have a high risk of local failure and alternative therapies should be considered in these patients, if available. Patients with central tumours, and those with decreased pre-treatment vision should be counselled on the risk of visual impairment.
Authors
- Leonoor Koetsier
- Ellen M. Kerkhof (ORCID: https://orcid.org/0000-0002-6070-7732)
- Heloisa H. Deuzeman (ORCID: https://orcid.org/0000-0003-3282-8497)
- Lennart J. Pors (ORCID: https://orcid.org/0000-0003-0907-6637)
- C. Rasch (ORCID: https://orcid.org/0000-0001-6950-3376)
- M. Marinkovic
- Jan‐Willem M. Beenakker (ORCID: https://orcid.org/0000-0003-0479-5587)
- T. H. Khanh Vu (ORCID: https://orcid.org/0000-0003-1809-4001)
- G.P.M. Luyten
- Carien L. Creutzberg (ORCID: https://orcid.org/0000-0002-7008-4321)
- Nanda Horeweg (ORCID: https://orcid.org/0000-0002-8581-4753)
- Jaco C. Bleeker
- K M van Wieringen-Warmenhoven
Institutions
- Leiden University Medical Center (NL)
Publication Details
- Journal
- Clinical and Translational Radiation Oncology
- Published
- 2025-02-24
- DOI
- https://doi.org/10.1016/j.ctro.2025.100939
- Citations
- 2
- Primary Topic
- Ocular Oncology and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 3.41
Funders
- Varian Medical Systems
- KWF Kankerbestrijding